In preclinical and animal models, researchers study FOXO4-DRI to evaluate its ability to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 protein interaction. It has gained significant attention in gerontology and cellular aging research as a targeted “senolytic” peptide because of how it releases p53 from FOXO4 sequestration, directing senescent cells toward cell death while sparing non-senescent, healthy tissue and reversing tissue dysfunction associated with aging.

Current Areas of Investigation

• FOXO4-p53 peptide-protein binding inhibition

• Selective senolytic activity and targeted apoptosis of senescent cells

• Reversal of senescence-associated secretory phenotype (SASP)

• Tissue regeneration models in aged skeletal muscle and skin

Research Focus

Technical Specifications

• Appearance: Lyophilized white to off-white powder (for laboratory handling).

• Storage Requirements: Store desiccated at −20°C for long-term molecular stability, protected from light and moisture.

Research Disclaimer: FOXO4-DRI supplied by Nomad Clinical is intended exclusively for laboratory research purposes. It is not approved as a medicinal product or food supplement and is not intended for human or veterinary use. References to published scientific literature are provided for educational context only.